Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 283 clinical trials
AutoRun0147823

AutomationRun0147823

  • 0 views
  • 23 Dec, 2022
AutoRun0147831

AutomationRun0147831

  • 0 views
  • 10 Jan, 2023
  • 1 location
AutoRun0147832

AutomationRun0147832

  • 0 views
  • 19 Jan, 2023
  • 1 location
AutoRun138

AutomationRun138

  • 0 views
  • 18 Oct, 2023
AutoRun137

AutomationRun137

  • 0 views
  • 13 Sep, 2023
  • 1 location
Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19)

The objectives of this study are to evaluate the safety, tolerability and efficacy of AT-527 in older subjects (ages 45-80 years) with moderate COVID-19 and risk factors for poor outcomes (such as obesity (BMI>30), hypertension, diabetes or asthma). Eligible subjects will be randomized to blinded AT-527 (nucleotide analog) tablets or …

coronavirus infection
SARS
hypertension
asthma
acute respiratory syndrome (sars)
  • 0 views
  • 16 Feb, 2024
  • 10 locations
Study Condition

Study Condition

  • 0 views
  • 16 Feb, 2024
  • 1 location
Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection

Synairgen has conducted randomised placebo controlled clinical trials of SNG001 involving >200 asthma and COPD patients. These trials have shown that SNG001 has: been well tolerated during virus infections enhanced antiviral activity in the lungs (measured in sputum and blood samples) provided significant lung function benefit over placebo in asthma

cancer
middle east respiratory syndrome
liver disease
chronic obstructive pulmonary disease
immunodeficiency
  • 0 views
  • 01 Feb, 2023
  • 9 locations
Safety Tolerability and Pharmacokinetic of Recombinant Anti-IL-5 Humanized Monoclonal Antibody Injection

This study is Safety, Tolerability and Pharmacokinetic of Recombinant anti-IL-5 Humanized Monoclonal Antibody injection in Healthy Subjects. There are 6 Groups as follows: 0.03mg/kg (S1), 0.2mg/kg (S2), 1.0mg/kg (S3), 3.0mg/kg (S4), 5.0mg/kg (S5) and 7.5mg/kg (S6); and 2 subjects were included in the S1 group (both received study drugs); 10 …

  • 0 views
  • 16 Feb, 2024
  • 1 location
Fiber Metabolism in Chronic Obstructive Pulmonary Disease

The impact of fiber intake on short chain fatty acid (SCFA) metabolism has not been studied in subjects suffering from COPD. The purpose of this study is to compare changes in SCFA metabolism after inulin vs. placebo intake in COPD patients to healthy matched controls. This protocol is an extension …

pulmonary disease
lung disorder
  • 0 views
  • 16 Feb, 2024
  • 1 location